PE20141549A1 - VARIANTES DE CRIg MADURAS POR AFINIDAD - Google Patents
VARIANTES DE CRIg MADURAS POR AFINIDADInfo
- Publication number
- PE20141549A1 PE20141549A1 PE2014000442A PE2014000442A PE20141549A1 PE 20141549 A1 PE20141549 A1 PE 20141549A1 PE 2014000442 A PE2014000442 A PE 2014000442A PE 2014000442 A PE2014000442 A PE 2014000442A PE 20141549 A1 PE20141549 A1 PE 20141549A1
- Authority
- PE
- Peru
- Prior art keywords
- mature
- affinity
- amino acids
- seq
- substitution
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 238000006467 substitution reaction Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102200058227 rs773814837 Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5088808P | 2008-05-06 | 2008-05-06 | |
| US18965308P | 2008-08-20 | 2008-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141549A1 true PE20141549A1 (es) | 2014-10-25 |
Family
ID=41168511
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000442A PE20141549A1 (es) | 2008-05-06 | 2009-05-06 | VARIANTES DE CRIg MADURAS POR AFINIDAD |
| PE2009000626A PE20091923A1 (es) | 2008-05-06 | 2009-05-06 | VARIANTES DE CRIg MADURAS POR AFINIDAD |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000626A PE20091923A1 (es) | 2008-05-06 | 2009-05-06 | VARIANTES DE CRIg MADURAS POR AFINIDAD |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9234024B2 (enExample) |
| EP (2) | EP3141560A3 (enExample) |
| JP (2) | JP5836800B2 (enExample) |
| KR (2) | KR101690590B1 (enExample) |
| CN (2) | CN104558151A (enExample) |
| AR (1) | AR071635A1 (enExample) |
| AU (1) | AU2009244300B2 (enExample) |
| BR (1) | BRPI0912003A2 (enExample) |
| CA (1) | CA2720685C (enExample) |
| CL (1) | CL2009001083A1 (enExample) |
| CY (1) | CY1118240T1 (enExample) |
| DK (1) | DK2280996T3 (enExample) |
| ES (1) | ES2605471T3 (enExample) |
| HK (1) | HK1210184A1 (enExample) |
| HR (1) | HRP20161580T1 (enExample) |
| HU (1) | HUE030092T2 (enExample) |
| IL (2) | IL208379A (enExample) |
| LT (1) | LT2280996T (enExample) |
| MX (1) | MX2010011372A (enExample) |
| PE (2) | PE20141549A1 (enExample) |
| PL (1) | PL2280996T3 (enExample) |
| PT (1) | PT2280996T (enExample) |
| RU (2) | RU2553517C2 (enExample) |
| SG (1) | SG190596A1 (enExample) |
| SI (1) | SI2280996T1 (enExample) |
| TW (1) | TWI508973B (enExample) |
| WO (1) | WO2009137605A2 (enExample) |
| ZA (1) | ZA201006937B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104231085B (zh) * | 2013-09-05 | 2017-03-15 | 复旦大学附属肿瘤医院 | 靶向特异性补体系统抑制剂、其制备方法及应用 |
| CA3159053A1 (en) * | 2019-12-06 | 2021-06-10 | Sui Yi Kwok | Method of treating inflammatory bowel disease |
| CN113583107B (zh) * | 2021-07-28 | 2023-11-10 | 复旦大学 | CRIg功能区蛋白变体及其应用 |
| WO2023080788A1 (en) * | 2021-11-05 | 2023-05-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Tryptophan depletion induces production and presentation of tryptophan to phenylalanine substitutions |
| TW202417510A (zh) * | 2022-09-20 | 2024-05-01 | 美商威特拉公司 | 用ｃ３ｂ抗體治療補體介導之疾病及病症 |
| TW202523706A (zh) * | 2023-11-13 | 2025-06-16 | 大陸商瀋陽三生製藥有限責任公司 | 一種靶向C3b的雙功能融合蛋白及其製備方法與用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4579827A (en) | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| EP0199141A3 (en) | 1985-04-19 | 1988-07-20 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancer |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4973478A (en) | 1987-07-20 | 1990-11-27 | Allelix Biopharmaceuticals, Inc. | Treating inflammation with hepatocyte stimulating factor interferon β2 |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| WO1990005537A1 (en) | 1988-11-16 | 1990-05-31 | Brigham And Women's Hospital | Inhib, a factor which inhibits cytokine-activated leukocytes |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| GB8922987D0 (en) * | 1989-10-12 | 1989-11-29 | Imutran Ltd | Modified biological material |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69326937T2 (de) | 1993-03-24 | 2000-12-28 | Berlex Biosciences, Richmond | Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung |
| US5650295A (en) | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP0824583A1 (en) | 1995-05-04 | 1998-02-25 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
| SE9604470D0 (sv) | 1996-12-04 | 1996-12-04 | Tamas Bartfai Konsulting Ab | Transmembrane component of tight junction |
| JP2001524814A (ja) | 1997-03-14 | 2001-12-04 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ２８種類のヒト分泌タンパク質 |
| JP2002503955A (ja) | 1997-03-21 | 2002-02-05 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
| WO1999002561A1 (en) | 1997-07-10 | 1999-01-21 | Smithkline Beecham Corporation | Human f11 antigen: a cell surface receptor involved in platelet aggregation |
| US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
| EP2014677A1 (en) | 1997-11-21 | 2009-01-14 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
| US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
| US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
| US7419663B2 (en) * | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
| US8088386B2 (en) * | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| AU2577799A (en) | 1998-02-09 | 1999-08-23 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| US6022708A (en) | 1998-02-26 | 2000-02-08 | Genentech, Inc. | Fused |
| PT1490386E (pt) | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
| EP1108019A2 (en) | 1998-08-27 | 2001-06-20 | Incyte Pharmaceuticals, Inc. | Protein transport-associated molecules |
| WO2000029583A2 (en) | 1998-11-19 | 2000-05-25 | Incyte Pharmaceuticals, Inc. | Immunoglobulin superfamily proteins |
| MXPA01006057A (es) | 1998-12-16 | 2003-09-10 | Genentech Inc | Polipeptidos secretados y transmembranales y acidos nucleicos que los codifican. |
| AU768230B2 (en) | 1998-12-22 | 2003-12-04 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2004516227A (ja) | 1999-03-08 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 免疫関連疾患を治療するための組成物と方法 |
| CA2388777A1 (en) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 18 human secreted proteins |
| EP1250426A2 (en) | 1999-12-01 | 2002-10-23 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding same |
| EP1309620A2 (en) | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
| WO2004022594A2 (en) * | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
| JP2010505743A (ja) * | 2006-06-01 | 2010-02-25 | ジェネンテック インコーポレイテッド | ＣＲＩｇ及びＣ３ｂ：ＣＲＩｇ複合体の結晶構造 |
| US7776573B2 (en) | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
| AU2008247958A1 (en) | 2007-05-01 | 2008-11-13 | Genentech, Inc. | CRIg antagonists |
-
2009
- 2009-05-06 EP EP16173577.4A patent/EP3141560A3/en not_active Withdrawn
- 2009-05-06 HU HUE09743591A patent/HUE030092T2/en unknown
- 2009-05-06 RU RU2010149804/10A patent/RU2553517C2/ru not_active IP Right Cessation
- 2009-05-06 PE PE2014000442A patent/PE20141549A1/es not_active Application Discontinuation
- 2009-05-06 LT LTEP09743591.1T patent/LT2280996T/lt unknown
- 2009-05-06 MX MX2010011372A patent/MX2010011372A/es active IP Right Grant
- 2009-05-06 US US12/387,794 patent/US9234024B2/en not_active Expired - Fee Related
- 2009-05-06 AU AU2009244300A patent/AU2009244300B2/en not_active Ceased
- 2009-05-06 RU RU2015117054/10A patent/RU2015117054A/ru not_active Application Discontinuation
- 2009-05-06 CN CN201410686051.4A patent/CN104558151A/zh active Pending
- 2009-05-06 CN CN200980116490.9A patent/CN102015763B/zh not_active Expired - Fee Related
- 2009-05-06 SG SG2013032388A patent/SG190596A1/en unknown
- 2009-05-06 ES ES09743591.1T patent/ES2605471T3/es active Active
- 2009-05-06 PL PL09743591T patent/PL2280996T3/pl unknown
- 2009-05-06 AR ARP090101632A patent/AR071635A1/es unknown
- 2009-05-06 KR KR1020107027276A patent/KR101690590B1/ko not_active Expired - Fee Related
- 2009-05-06 KR KR1020167035910A patent/KR20170001711A/ko not_active Ceased
- 2009-05-06 TW TW098115004A patent/TWI508973B/zh not_active IP Right Cessation
- 2009-05-06 PE PE2009000626A patent/PE20091923A1/es not_active Application Discontinuation
- 2009-05-06 HR HRP20161580TT patent/HRP20161580T1/hr unknown
- 2009-05-06 BR BRPI0912003A patent/BRPI0912003A2/pt not_active IP Right Cessation
- 2009-05-06 PT PT97435911T patent/PT2280996T/pt unknown
- 2009-05-06 EP EP09743591.1A patent/EP2280996B1/en active Active
- 2009-05-06 JP JP2011508636A patent/JP5836800B2/ja not_active Expired - Fee Related
- 2009-05-06 WO PCT/US2009/043020 patent/WO2009137605A2/en not_active Ceased
- 2009-05-06 CL CL2009001083A patent/CL2009001083A1/es unknown
- 2009-05-06 SI SI200931567A patent/SI2280996T1/sl unknown
- 2009-05-06 DK DK09743591.1T patent/DK2280996T3/en active
- 2009-05-06 CA CA2720685A patent/CA2720685C/en not_active Expired - Fee Related
-
2010
- 2010-09-29 ZA ZA2010/06937A patent/ZA201006937B/en unknown
- 2010-10-03 IL IL208379A patent/IL208379A/en not_active IP Right Cessation
-
2015
- 2015-02-09 JP JP2015023559A patent/JP2015145369A/ja active Pending
- 2015-04-20 US US14/690,891 patent/US20160008427A1/en not_active Abandoned
- 2015-10-29 HK HK15110724.5A patent/HK1210184A1/xx unknown
-
2016
- 2016-11-17 CY CY20161101186T patent/CY1118240T1/el unknown
- 2016-12-11 IL IL249492A patent/IL249492A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125327A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
| CL2018000537A1 (es) | Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009). | |
| CL2013001673A1 (es) | Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición. | |
| MX346862B (es) | Secuencias consenso de envoltura de vih y método para usar las mismas. | |
| PE20090711A1 (es) | Region constante de anticuerpo mutante | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA200970581A1 (ru) | Кристаллическое твёрдое основание разагилина | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| PE20141549A1 (es) | VARIANTES DE CRIg MADURAS POR AFINIDAD | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| PE20140867A1 (es) | Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas y metodos para su uso | |
| ATE485304T1 (de) | Muteine von tearlipocalin und verfahren zu deren gewinnung | |
| AR064642A1 (es) | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| EA201000427A1 (ru) | Секвенирование нуклеиново-кислотных полимеров с использованием электронной микроскопии | |
| MY148096A (en) | 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments | |
| MX2016002636A (es) | Polipeptido para la escision hidrolitica de la zearalenona y/o derivados de la zearalenona, polinucleotido aislado de la misma y polieptido que contiene aditivo, uso y procedimiento de los mismos. | |
| PE20081723A1 (es) | Vacuna contra el papilomavirus | |
| BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
| MX385354B (es) | Sales de xantilio 3,6-disustituidas. | |
| CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
| PE20131065A1 (es) | Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |